Skip to main content

Ifosfamid (z.B. Holoxan™)

  • Chapter
  • 19 Accesses

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Primärliteratur

  1. Bertelli G, Gozza A, Forno GB,Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13: 2851–2855, 1995.

    Google Scholar 

  2. Marnocha RS, Hutson PR: Intradermal carboplatin and ifosfamide extravasation in the mouse. Cancer 70: 850–853, 1992.

    Article  PubMed  CAS  Google Scholar 

  3. Bertelli G, Dini D, Forno G, Dimethylsulphoxide and cooling after extravasation of antitumour agents. Lancet 341: 1098–1099, 1993.

    Google Scholar 

  4. Brock N, Hilgard P, Peukert M, Basis and new developments in the field of oxazaphosphorines. Cancer Invest 6: 513–532, 1988.

    Google Scholar 

  5. Mateu J, Alzamora M, Franco M, Ifosfamide extravasation. Ann Pharmacother 28: 1243–1244, 1994.

    Google Scholar 

Sekundärliteratur

  1. Asta Medica, persönliche Mitteilung, November 1998.

    Google Scholar 

  2. The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.

    Google Scholar 

  3. The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 274–276, 1997.

    Google Scholar 

  4. Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.

    Article  PubMed  CAS  Google Scholar 

  5. Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (Hrsg) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, Band 1, 2. Auflage: A42–44, 1997.

    Google Scholar 

  6. ]Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.

    Google Scholar 

  7. ]Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.

    Google Scholar 

  8. Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 558–563, 1994.

    Google Scholar 

  9. ZytostatikaHerstellung in der Apotheke. Deutscher Apotheker Verlag, Kap. VI-3: 1–9, 2000.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Wien

About this chapter

Cite this chapter

Mader, I., Fürst-Weger, P., Mader, R.M., Semenitz, E.I., Terkola, R., Wassertheurer, S.M. (2002). Ifosfamid (z.B. Holoxan™). In: Paravasation von Zytostatika. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3799-4_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3799-4_33

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-3800-7

  • Online ISBN: 978-3-7091-3799-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics